KAHR Announces Publication of Preclinical Data Indicating Monotherapy and Combination Treatment Potential of its Investigational Anti-CD47 Fusion Protein
Ticker Tech,
Results published in Journal of Experimental
Results published in Journal of Experimental
Results published in Journal of Experimental
JERUSALEM, March 15, 2022 /PRNewswire/ -- KAHR, a clinical stage cancer immunotherapy company developing novel dual-targeting…
JERUSALEM, March 15, 2022 /PRNewswire/ -- KAHR, a clinical stage cancer immunotherapy company developing novel dual-targeting…